Enrique Fisman
Enrique Fisman
Bestätigte E-Mail-Adresse bei - Startseite
Zitiert von
Zitiert von
Sudden unexpected death in persons< 40 years of age
Y Drory, Y Turetz, Y Hiss, B Lev, EZ Fisman, A Pines, MR Kramer
The American journal of cardiology 68 (13), 1388-1392, 1991
Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome
A Tenenbaum, M Motro, EZ Fisman, D Tanne, V Boyko, S Behar
Archives of internal medicine 165 (10), 1154-1160, 2005
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
A Tenenbaum, M Motro, EZ Fisman
Cardiovascular diabetology 4 (1), 1-5, 2005
Ischemic preconditioning: nearly two decades of research. A comprehensive review
A Eisen, EZ Fisman, M Rubenfire, D Freimark, R McKechnie, ...
Atherosclerosis 172 (2), 201-210, 2004
Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease?
EZ Fisman, A Tenenbaum
Cardiovascular diabetology 13 (1), 1-10, 2014
The effects of hormone replacement therapy in normal postmenopausal women: measurements of Doppler-derived parameters of aortic flow
A Pines, EZ Fisman, Y Levo, M Averbuch, A Lidor, Y Drory, A Finkelstein, ...
American journal of obstetrics and gynecology 164 (3), 806-812, 1991
Peroxisome proliferator–activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease
A Tenenbaum, M Motro, EZ Fisman, E Schwammenthal, Y Adler, ...
Circulation 109 (18), 2197-2202, 2004
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
A Tenenbaum, R Klempfner, EZ Fisman
Cardiovascular diabetology 13 (1), 1-10, 2014
Elevated triglyceride level is independently associated with increased all-cause mortality in patients with established coronary heart disease: twenty-two–year follow-up of the …
R Klempfner, A Erez, BZ Sagit, I Goldenberg, E Fisman, E Kopel, ...
Circulation: Cardiovascular Quality and Outcomes 9 (2), 100-108, 2016
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
A Tenenbaum, EZ Fisman
Cardiovascular diabetology 11 (1), 1-10, 2012
Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level
A Hiuge, A Tenenbaum, N Maeda, M Benderly, M Kumada, EZ Fisman, ...
Arteriosclerosis, Thrombosis, and Vascular Biology 27 (3), 635-641, 2007
Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction
EZ Fisman, M Benderly, RJ Esper, S Behar, V Boyko, Y Adler, D Tanne, ...
The American journal of cardiology 98 (1), 14-18, 2006
Calcification of the thoracic aorta as detected by spiral computed tomography among stable angina pectoris patients: association with cardiovascular events and death
A Eisen, A Tenenbaum, N Koren-Morag, D Tanne, J Shemesh, M Imazio, ...
Circulation 118 (13), 1328-1334, 2008
Myocardial ischemia during sexual activity in patients with coronary artery disease
Y Drory, I Shapira, EZ Fisman, A Pines
The American journal of cardiology 75 (12), 835-837, 1995
Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
A Tenenbaum, EZ Fisman, M Motro
Cardiovascular diabetology 2 (1), 1-7, 2003
Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis
EZ Fisman, M Motro, A Tenenbaum, V Boyko, L Mandelzweig, S Behar
American heart journal 141 (3), 485-490, 2001
Oral antidiabetic treatment in patients with coronary disease: time‐related increased mortality on combined glyburide/metformin therapy over a 7.7‐year follow‐up
EZ Fisman, A Tenenbaum, Y Adler, M Motro, V Boyko, M Benderly, ...
Clinical cardiology 24 (2), 151-158, 2001
Functional class in patients with heart failure is associated with the development of diabetes
A Tenenbaum, M Motro, EZ Fisman, J Leor, D Freimark, V Boyko, ...
The American journal of medicine 114 (4), 271-275, 2003
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
A Tenenbaum, EZ Fisman
Cardiovascular Diabetology 11 (1), 1-9, 2012
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
A Tenenbaum, EZ Fisman, M Motro, Y Adler
Cardiovascular diabetology 5 (1), 1-8, 2006
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20